MYC and myeloid neoplasm: This supports why many solid and liquid cancers are considered “addicted” to c-Myc, which just so happens to have coined the term for “oncogene addiction.”251 In 1999, Felsher and Bishop reported that in hematopoietic cells of transgenic mice the expression of c-Myc leads to lymphoid and myeloid malignancies and that this process was reversible when c-Myc expression was terminated.265 Even with concerns of inhibition leading to off-target toxicity, it has continued to develop as a desirable target for AML treatment.